Athanor Capital, LP Blueprint Medicines Corp Transaction History

Athanor Capital, LP

7 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2021 Aug 16, 2021	SELL	$82.78 - $101.0 $599,078 - $730,937	-7,237 Closed	0 $0
Q1 2021 May 14, 2021	BUY	$90.71 - $108.28 $56,603 - $67,566	624 Added 9.44%	7,237 $704,000
Q4 2020 Feb 16, 2021	BUY	$92.08 - $124.48 $608,925 - $823,186	6,613 New	6,613 $742,000
Q1 2020 May 14, 2020	SELL	$48.11 - $82.22 $495,533 - $846,866	-10,300 Closed	0 $0
Q4 2019 Feb 14, 2020	BUY	$66.73 - $82.59 $233,555 - $289,065	3,500 Added 51.47%	10,300 $825,000
Q3 2019 Nov 14, 2019	BUY	$72.9 - $101.41 $123,930 - $172,397	1,700 Added 33.33%	6,800 $500,000
Q2 2019 Aug 13, 2019	BUY	$73.54 - $97.8 $375,054 - $498,780	5,100 New	5,100 $481,000

351

60.3M

2.25M

1.18M

Ticker BPMC
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 59,719,600
Market Cap $5.4B
Description
Blueprint Medicines Corporation, a precision therapy company, develops medicines for genomically defined cancers and blood disorders in the United States and internationally. The company is developing AYVAKIT for the treatment of systemic mastocytosis (SM) and gastrointestinal stromal tumors; BLU-263, an orally available, potent, and KIT inhibit...

Get notified when there are updates to the investment portfolio of Athanor Capital, LP, based on Form 13F filings with the SEC.

Stay updated on Athanor Capital, LP with notifications on news.